CVR 31332761Private limited company (ApS)Anden forskning og eksperimentel udvikling inden for naturvidenskab og teknik (721900)Østergade 24, 1100 København KFounded 25 Feb 2008
Employees
0
CVR, 2015
Compare withsimilar companiesanother companyits industry
H PHARMACEUTICALS GENERAL PARTNER ApS
CVR registers no owner holding 5% or more.
The newest trades with a company on a side are on the latest property trades.
Compiled by Dandex from the Danish Business Registry (CVR, datacvr.virk.dk), Erhvervsstyrelsen, and annual reports filed in XBRL. Values marked Dandex estimate are computed by Dandex from that data, not registered.
Cite as: H PHARMACEUTICALS GENERAL PARTNER ApS, https://dandex.ai/company/31332761/h-pharmaceuticals-general-partner. Source: Dandex, from CVR, read 22 Nov 2026.
Dandex is Danish Company Data. Connect it once and ask about H PHARMACEUTICALS GENERAL PARTNER ApS, or any Danish company, from your assistant, the API or the command line. Answers come from the current record: owners and the ownership network, financials year by year, and the latest registered changes.
Dandex has an MCP server at https://dandex.ai/mcp and a REST API at https://dandex.ai/api/v1.
Set up DandexCVR registers no owner holding 5% or more.
John Barberichuntil 7 Aug 2012
Wyle Solomonuntil 7 Aug 2012
CVR lists no current officers for this company.
Founded 25 Feb 2008.
CVR records founders at incorporation. It does not record whether they are alive or still involved.
Jun 2015, monthly: 0 employees, 1 FTE
Arrow keys move through the periods, Home and End go to the first and the latest, Escape returns to the latest.
| Period | Q4 2009 | Q1 2010 | Q2 2010 | Q3 2010 | 2011 | 2012 | Jun 2015 |
|---|---|---|---|---|---|---|---|
| Employees | No count | No count | No count | No count | 1 | 0 | 0 |
| FTE | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
| Series | Quarterly | Quarterly | Quarterly | Quarterly | Annual | Annual | Monthly |
The legal entity's headcount in CVR, not the annual report's average, which may cover a group.
Source: CVR, latest Jun 2015, published 20 Nov 2015.
Not available in the CVR filing: the annual reports carry no machine-readable figures.
Annual report 2010
Published 24 May 2011
Annual report 2009
Published 4 May 2010
Annual report 2008
25 Feb 2008 to 31 Dec 2008, published 18 May 2009
Amounts in DKK.
| Date | Change | Cash price | Paid in | Implied value | Capital after |
|---|---|---|---|---|---|
| FoundingNot read from the announcement | None | None | None | 125,000 |
Source: Erhvervsstyrelsen's announcements, shown where the amounts add up to the registered capital.
No changes since Dandex began following this company. For announcements from before then, see Registrations.
Pro: Signals (signaler) are in the Pro plan, see pricingChanges worth a look, raised from the registry and new annual reports.
New leadership (nyt lederskab), New company (ny virksomhed), Ownership change (ejerskifte), Relocation (flytning), Growth surge (vækstspurt), Headcount decline (nedgang i ansatte), Restructuring (omstrukturering), Industry change (brancheskift), Board change (bestyrelsesændring), Dissolution (ophør), Distress warning (risikoadvarsel), Fund investment (fondsinvestering), Fund exit (fondsexit), Fund board seat (fondsbestyrelsespost).
Decided by Dandex from CVR and the filed annual reports, not registered by the company.
Fixed rules decide most of these. The auditor's report, the business model, the revenue model and the activity in its own words are read by a calibrated decision model from the report's text and the purpose clause. Each label links to its definition.
Source: CVR, read 22 Nov 2026.
10 registrations, as published by Erhvervsstyrelsen. People's street addresses are cut to postcode and city.
Konkursbehandlingen afsluttet 12.05.2015, virksomheden opløst
Konkursdekret afsagt 07.08.2012 af Sø- og Handelsrettens Skifteafdeling.
Vedtægter ændret:
10.01.2011.
Bestyrelse:
Udtrådt af bestyrelsen:
John Barberich, den 10.01.2011, Douglas Abel, den 04.01.2011, Enda Kenny, den 10.01.2011, Michael Gerard McGuinness, den 04.01.2011.
Direktion:
Indtrådt i direktionen:
John Barberich, den 10.01.2011, Wyle Solomon, den 10.01.2011.
Selskabet tegnes af 2 direktionsmedlemmer i forening.
Bestyrelse:
Udtrådt af bestyrelsen:
Florian Schønharting, den 06.10.2010.
Indtrådt i bestyrelsen:
Enda Kenny, den 06.10.2010.
Ny adresse:
c/o NB Capital ApS, Østergade 24A, 1. tv., 1100 København K.
Bestyrelse:
Udtrådt af bestyrelsen:
Christian Karsten Hansen, den 18.05.2009.
Indtrådt i bestyrelsen:
John Barberich, den 18.05.2009.
Vedtægter ændret:
26.11.2008.
Nyt navn:
H PHARMACEUTICALS GENERAL PARTNER ApS.
Stiftelsesdato:
25.02.2008.
Seneste vedtægtsdato:
25.02.2008.
Kapital:
kr. 125.000,00.
Indbetalingsmåde:
kontant kr. 125.000,00 til kurs 100,00.
Stiftere:
CVR-NR. 29150397 NORDIC BIOTECH VENTURE FUND II K/S, Østergade 5, 3., 1100 København K, den 25.02.2008, Manhattan Pharmaceuticals Inc, den 25.02.2008.
Bestyrelse:
Douglas Abel, den 25.02.2008, Direktør Christian Karsten Hansen, den 25.02.2008, Michael Gerard McGuinness, den 25.02.2008, Direktør Florian Schønharting, den 25.02.2008.
Selskabet tegnes af 2 bestyrelsesmedlemmer i forening.
Revision:
CVR-NR. 73317428 ERNST & YOUNG STATSAUTORISERET REVISIONSAKTIESELSKAB, Tagensvej 86, 2200 København N, den 25.02.2008.
Første regnskabsår:
25.02.2008 - 31.12.2008.
Regnskabsår:
01.01 - 31.12.
Counts include corrections, and an audit firm that re-registered under a new entity.
Source: CVR, read 22 Nov 2026.
What Pro holds for H PHARMACEUTICALS GENERAL PARTNER ApS:
Have Pro? Sign in.
P-number 1014307016Østergade 24, 1100 København K